Free tool
FAERS Monitor: Primaquine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 008316 or its brand name (Primaquine, Primaquine Phosphate). Reports on generic versions are filed under their own applications.
Reports
87
Serious
76
87% of reports
Hospitalization
30
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- methaemoglobinaemia20
- drug ineffective13
- drug interaction12
- pyrexia10
- cyanosis8
- plasmodium vivax infection7
- chromaturia6
- dyspnoea6
- off label use6
- drug eruption5
- headache5
- hyponatraemia4
- neutropenia4
- syncope4
- decreased appetite3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 33 |
| 2022 | 9 |
| 2023 | 1 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,072 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasmodium vivax infectionSignal | 7 | 105875.4 | 44668.9 | 444,536 |
| methaemoglobinaemiaSignal | 20 | 2107.1 | 1431.2 | 39,681 |
| cyanosisSignal | 8 | 123.0 | 63.6 | 850 |
| drug eruptionSignal | 5 | 68.2 | 29.1 | 268 |
| chromaturiaSignal | 6 | 64.3 | 29.7 | 313 |
| drug interactionSignal | 12 | 18.3 | 10.8 | 181 |
| hyponatraemiaSignal | 4 | 17.2 | 6.6 | 46 |
| syncopeSignal | 4 | 9.7 | 3.7 | 23 |
| neutropeniaSignal | 4 | 7.1 | 2.7 | 15 |
| pyrexiaSignal | 10 | 7.0 | 3.9 | 46 |
| decreased appetite | 3 | 3.1 | 1.0 | 2 |
| dyspnoeaSignal | 6 | 2.6 | 1.2 | 4 |
| drug ineffectiveSignal | 13 | 2.4 | 1.4 | 10 |
| headache | 5 | 1.9 | 0.8 | 1 |
| off label use | 6 | 1.7 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.